GATC Health Welcomes Coverage by South Asian Herald Highlighting Its Visionary AI Strategy
DATE
Nov 17, 2025
CATEGORY
Company
Former U.S. “Drug Czar” Dr. Rahul Gupta brings expertise in public health and addiction medicine to lead GATC Health's push for faster, safer therapies for chronic and rare diseases.
November 17, 2025
GATC Health is pleased to announce significant media coverage in the South Asian Herald, spotlighting President Dr. Rahul Gupta’s leadership as the company accelerates its mission to transform drug discovery for chronic and rare diseases using advanced artificial intelligence. The publication’s article, “Dr. Rahul Gupta Leads GATC Health’s Push to Revolutionize Drug Discovery for Chronic and Rare Diseases with AI,” underscores GATC Health’s growing international impact and the momentum behind its technology-driven approach.
The feature highlights how GATC Health’s AI-powered drug discovery engine models human biology in silico to assess the safety and efficacy of compounds with unprecedented precision, enabling dramatically faster and more cost-effective development. It also explores the role of the company’s Derisq™ predictive analytics platform in forecasting disease risk and treatment response, advancing GATC Health’s goal of making innovative therapies more accessible across global markets.
Dr. Gupta shared his perspective on the company’s mission, stating, “We are entering a new era where AI allows us to understand human biology at a depth once thought impossible. Our goal is to harness that capability to bring safer, more effective medicines to patients everywhere, especially those living with conditions that have lacked meaningful innovation for far too long.”
He added, “This coverage highlights not only our technology but also the urgent global need we are committed to addressing. We are grateful for the opportunity to share our vision and accelerate the impact we know this science can deliver.”
Media attention such as this marks an important milestone as GATC Health continues to expand partnerships and advance its research pipeline worldwide. The South Asian Herald’s coverage underscores the company’s long-standing belief that AI-driven biomedical innovation should serve as a global public good, supporting healthier futures in both developed and emerging regions.
About GATC Health
GATC Health is a tech-bio company revolutionizing drug discovery and development by simulating complex human biology to predict how drugs will perform in the body, achieving 91% specificity and 86% sensitivity. Trusted by the world’s largest insurance marketplace, biopharma, researchers, and investment partners, GATC Health's risk prediction product, the Derisq™ AI report, accurately assesses and predicts drug candidate safety, efficacy, and non-obvious side effects prior to the commitment of development capital. GATC Health’s AI platform is also generative, creating novel intellectual property, extending pipelines, and optimizing assets. By uniting advanced AI, multiomics, and predictive modeling, GATC Health accelerates breakthroughs and reduces costly late-stage failures to bring safer, more effective therapies to patients worldwide. For more information, visit www.gatchealth.com.
Related articles
Contacts
Join Us in Transforming
Healthcare Through Advanced AI
We're always on the lookout for like-minded partners committed to making healthcare better, more efficient, and safer. Reach out today to see how our specialized AI solutions can be tailored to your needs.
